Eisai's Banzel gets US approval and complete response letter for epilepsy
This article was originally published in Scrip
Eisai'santiconvulsant Banzel (rufinamide) has received approval from the US FDA as an adjunctive treatment for of seizures associated with a severe form of epilepsy, Lennox-Gastaut syndrome (LGS), in patients aged four years and older. It will be launched in the US in 2009.
You may also be interested in...
Beyond Epidiolex for severe epilepsy, cannabinoid candidates are in development for a range of diseases, including acute pain, graft-versus-host disease, scleroderma, schizophrenia, pain and substance use disorder.
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.